Could immunotherapy boost radiation for head and neck cancer?

NCT ID NCT01810913

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 15 times

Summary

This study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will participate after surgery. The goal is to see which combination best prevents cancer from returning and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: radiation therapy with cisplatin, docetaxel, cetuximab, or atezolizumab
What this could lead to: If successful, this could point toward a more effective treatment plan for high-risk head and neck cancer, potentially improving survival and reducing recurrence.
What could go wrong: This is a large but still early-stage trial; the experimental combinations may not prove better than standard care, and side effects from chemotherapy and immunotherapy can be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 613 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2013

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PHASE II INCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020) * Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx * Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible * Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink) * Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup: * General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration; * Examination by an ear nose throat (ENT) or head \& neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation * Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave * Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement * Zubrod performance status of 0-1 within 14 days prior to registration * Age \>= 18 * Absolute granulocyte count (AGC) \>= 1,500 cells/mm\^3 (obtained within 14 days prior to registration on study) * Platelets \>= 100,000 cells/mm\^3 (obtained within 14 days prior to registration on study) * Hemoglobin \>= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable) * Total bilirubin \< 2 x institutional upper limit of normal (ULN) within 14 days prior to registration * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 3 x institutional ULN within 14 days prior to registration * Serum creatinine institutional ULN within 14 days prior to registration or; creatinine clearance (CC) \>= 50 ml/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula * Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential * The following assessments are required within 14 days prior to registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; Note: patients with an initial magnesium \< 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator's discretion * Patients with feeding tubes are eligible for the study * Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control * Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis * PHASE III: Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx * PHASE III: Patients with oropharyngeal cancer must have p16-negative based on central review prior to Step 2 registration. All patients with oropharyngeal primary must consent for mandatory tissue submission for central p16 confirmation * PHASE III: Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration * Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection. The gross total resection has to be done within 63 days prior to registration. If, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible * PHASE III: Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink or tumor in a final separately submitted margin) * PHASE III: Pathologic stage III or IV HNSCC (American Joint Committee on Cancer \[AJCC\] 7th edition), including no distant metastases, based upon the following minimum diagnostic workup: * General history and physical examination by a radiation oncologist or medical oncologist within 84 days prior to registration; * Examination by an ENT or head \& neck surgeon prior to surgery; a laryngopharyngoscopy (mirror or fiberoptic or direct procedure), if appropriate, is recommended but not required. Intra-operative examination is acceptable documentation. * Pre-op Imaging of the head and neck: A neck CT (with contrast and of diagnostic quality) or PET/CT (with contrast and of diagnostic quality) and/or an MRI of the neck of diagnostic quality (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in DICOM format via TRIAD. The report is to be uploaded into Rave. * Chest CT scan (with or without contrast) or PET/CT that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: If the PET/CT with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement * PHASE III: Zubrod performance status of 0-1 within 14 days prior to registration * PHASE III: Age \>= 18 * PHASE III: Leukocytes \>= 2,500 cells/mm\^3 (obtained within 14 days prior to registration on study) * PHASE III: Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (obtained within 14 days prior to registration on study) * PHASE III: Platelets \>= 100,000 cells/mm\^3 (obtained within 14 days prior to registration on study) * PHASE III: Hemoglobin \>= 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb \>= 8.0 g/dL is acceptable) (obtained within 14 days prior to registration on study) * PHASE III: Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\< 3 x institutional ULN may be enrolled) (within 14 days prior to registration) * PHASE III: AST or ALT =\< 3 x institutional ULN (within 14 days prior to registration) * PHASE III: Alkaline phosphatase =\< 2.5 x institutional ULN (within 14 days prior to registration) * PHASE III: Creatinine clearance (CrCl) \>= 50 mL/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula * PHASE III: Patients with feeding tubes are eligible for the study * PHASE III: Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential * PHASE III: All patients must provide study specific informed consent prior to study entry * PHASE III: Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have: * A stable regimen of highly active anti-retroviral therapy (HAART); * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests Exclusion Criteria: * PHASE II EXCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020) * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years); noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated \< 3 years ago * Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible * Prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * Severe, active co-morbidity, defined as follows: * Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration * Transmural myocardial infarction within 6 months prior to registration * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immuno-compromised patients. * Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events \[CTCAE\], version \[v.\] 4): * Serum calcium (ionized or adjusted for albumin) \< 7 mg/dl (1.75 mmol/L) or \> 12.5 mg/dl (\> 3.1 mmol/L) despite intervention to normalize levels * Glucose \< 40 mg/dl (\< 2.2 mmol/L) or \> 250 mg/dl (\> 14 mmol/L) * Magnesium \< 0.9 mg/dl (\< 0.4 mmol/L) or \> 3 mg/dl (\> 1.23 mmol/L) despite intervention to normalize levels * Potassium \< 3.0 mmol/L or \> 6 mmol/L despite intervention to normalize levels * Sodium \< 130 mmol/L or \> 155 mmol/L despite intervention to normalize levels * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic * Prior allergic reaction to cetuximab * PHASE III: Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) with the following exceptions: T1-2, N0, M0 resected differentiated thyroid carcinoma; Note that noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix) are permitted even if diagnosed and treated \< 3 years ago * PHASE III: Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible * PHASE III: Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy (such as anti-EGF therapy), or immune therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, a prior anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is not permitted * PHASE III: Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * PHASE III: Severe, active co-morbidity, defined as follows: * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification; to be eligible for this trial, patients should be class 2B or better within 6 months prior to registration * Transmural myocardial infarction within 6 months prior to registration; * Severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia; * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible. * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; * History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in a prior radiation field (fibrosis) is permitted, provided that field does not overlap with the planned radiation field for the study cancer; * Patients with active tuberculosis (TB) are excluded; * Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \[HBsAg\] test and a positive anti-HBc \[antibody to hepatitis B core antigen\] antibody test) are eligible. * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. * History of allogeneic bone marrow transplantation or solid organ transplantation. * A diagnosis of immunodeficiency: * Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note: HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. * Is receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] agents) within 2 weeks prior to registration. * Note: Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. * Note: The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. * History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. * Patients with a history of autoimmune hypothyroidism who are asymptomatic and/or are on a stable dose of thyroid replacement hormone are eligible. * Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible. * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations * Rash must cover less than 10% of body surface area (BSA) * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%) * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \[PUVA\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) * PHASE III: Grade 3-4 electrolyte abnormalities (CTCAE, v. 4) within 14 days prior to registration: * Serum calcium (ionized or adjusted for albumin) \< 7 mg/dL (1.75 mmol/L) or \> 12.5 mg/dL (\> 3.1 mmol/L) despite intervention to normalize levels; * Glucose \< 40 mg/dL (\< 2.2 mmol/L) or \> 250 mg/dL (\> 14 mmol/L); * Magnesium \< 0.9 mg/dL (\< 0.4 mmol/L) or \> 3 mg/dL (\> 1.23 mmol/L) despite intervention to normalize levels; * Potassium \< 3.0 mmol/L or \> 6 mmol/L despite intervention to normalize levels; * Sodium \< 130 mmol/L or \> 155 mmol/L despite intervention to normalize levels. * PHASE III: Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for up to 5 months from last study treatment; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding and unwilling to discontinue are also excluded * PHASE III: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * PHASE III: Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other non-oncologic reasons (e.g., osteoporosis) is allowed * PHASE III: Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) for non-oncologic reasons who cannot discontinue it before registration * PHASE III: Patients with known distant metastatic disease are excluded * PHASE III: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * PHASE III: Major surgical procedure within 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study * PHASE III: Administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and for patients receiving atezolizumab, up to 5 months after the last dose of atezolizumab. * Influenza vaccination should be given during influenza season only (approximately October to

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma hypopharynx squamous cell carcinoma laryngeal squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

342 sites in 3 countries. The list below names each one and where it is.
The official record

The full official record for this study. This one lists no contact details, but it is the first place any would appear.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Adena Regional Medical Center

Chillicothe, Ohio, 45601, United States
AdventHealth Orlando

Orlando, Florida, 32803, United States
AdventHealth Parker

Parker, Colorado, 80138, United States
AdventHealth Porter

Denver, Colorado, 80210, United States
Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699, United States
Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, 68124, United States
Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1, Canada
Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States
Allegiance Health

Jackson, Michigan, 49201, United States
AnMed Health Cancer Center

Anderson, South Carolina, 29621, United States
Arnot Ogden Medical Center/Falck Cancer Center

Elmira, New York, 14905, United States
Ascension Saint Vincent Anderson

Anderson, Indiana, 46016, United States
Aspirus Cancer Care - Stevens Point

Stevens Point, Wisconsin, 54481, United States
Aspirus Cancer Care - Wisconsin Rapids

Wisconsin Rapids, Wisconsin, 54494, United States
Aspirus Cancer Care-Antigo-Volm Cancer Center

Antigo, Wisconsin, 54409, United States
Aspirus Cancer Care-Rhinelander-James Beck Cancer Center

Rhinelander, Wisconsin, 54501, United States
Aspirus Cancer Care-Wausau

Wausau, Wisconsin, 54401, United States
Atrium Health Cabarrus/LCI-Concord

Concord, North Carolina, 28025, United States
Atrium Health Pineville/LCI-Pineville

Charlotte, North Carolina, 28210, United States
Atrium Health Stanly/LCI-Albemarle

Albemarle, North Carolina, 28002, United States
Atrium Health Union/LCI-Union

Monroe, North Carolina, 28112, United States
Atrium Health University City/LCI-University

Charlotte, North Carolina, 28262, United States
Augusta University Medical Center

Augusta, Georgia, 30912, United States
Banner North Colorado Medical Center

Greeley, Colorado, 80631, United States
Banner North Colorado Medical Center - Loveland Campus

Loveland, Colorado, 80539, United States
Banner University Medical Center - Tucson

Tucson, Arizona, 85719, United States
Bay Area Medical Center

Marinette, Wisconsin, 54143, United States
Boston Medical Center

Boston, Massachusetts, 02118, United States
CHI Health Good Samaritan

Kearney, Nebraska, 68847, United States
Camden Clark Medical Center

Parkersburg, West Virginia, 26101, United States
Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carlisle Regional Cancer Center

Carlisle, Pennsylvania, 17015, United States
Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203, United States
Case Western Reserve University

Cleveland, Ohio, 44106, United States
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Central Maryland Radiation Oncology in Howard County

Columbia, Maryland, 21044, United States
Chinese University of Hong Kong-Prince of Wales Hospital

Shatin, Hong Kong
Christiana Care Health System-Christiana Hospital

Newark, Delaware, 19718, United States
Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015, United States
Cleveland Clinic Akron General

Akron, Ohio, 44307, United States
Cleveland Clinic Cancer Center Independence

Independence, Ohio, 44131, United States
Cleveland Clinic Cancer Center Strongsville

Strongsville, Ohio, 44136, United States
Cleveland Clinic Cancer Center/Fairview Hospital

Cleveland, Ohio, 44111, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Cleveland Clinic Wooster Family Health and Surgery Center

Wooster, Ohio, 44691, United States
Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, 56303, United States
Community Medical Center

Toms River, New Jersey, 08755, United States
Cooperman Barnabas Medical Center

Livingston, New Jersey, 07039, United States
Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085, United States
Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503, United States
Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073, United States
Covenant Medical Center-Lakeside

Lubbock, Texas, 79410, United States
CoxHealth South Hospital

Springfield, Missouri, 65807, United States
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Crossroads Cancer Center

Effingham, Illinois, 62401, United States
Dartmouth Cancer Center - North

Saint Johnsbury, Vermont, 05819, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756, United States
Decatur Memorial Hospital

Decatur, Illinois, 62526, United States
Drexel Town Square Health Center

Oak Creek, Wisconsin, 53154, United States
ECU Health Oncology Kinston

Kinston, North Carolina, 28501, United States
East Carolina University

Greenville, North Carolina, 27834, United States
Elkhart General Hospital

Elkhart, Indiana, 46515, United States
Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Froedtert Menomonee Falls Hospital

Menomonee Falls, Wisconsin, 53051, United States
Froedtert West Bend Hospital/Kraemer Cancer Center

West Bend, Wisconsin, 53095, United States
Geauga Hospital

Chardon, Ohio, 44024, United States
George Washington University Medical Center

Washington D.C., District of Columbia, 20037, United States
Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651, United States
Goshen Center for Cancer Care

Goshen, Indiana, 46526, United States
Greater Baltimore Medical Center

Baltimore, Maryland, 21204, United States
Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601, United States
HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269, United States
Helen F Graham Cancer Center

Newark, Delaware, 19713, United States
Hennepin County Medical Center

Minneapolis, Minnesota, 55415, United States
Henry Ford Cancer Institute-Downriver

Brownstown, Michigan, 48183, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038, United States
Henry Ford Medical Center-Columbus

Novi, Michigan, 48377, United States
Henry Ford Medical Center-Fairlane

Dearborn, Michigan, 48126, United States
Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322, United States
Henry Ford Wyandotte Hospital

Wyandotte, Michigan, 48192, United States
Highland Hospital

Rochester, New York, 14620, United States
Hillcrest Hospital Cancer Center

Mayfield Heights, Ohio, 44124, United States
Holy Cross Hospital

Fort Lauderdale, Florida, 33308, United States
Holy Cross Hospital

Silver Spring, Maryland, 20910, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
IRMC Cancer Center

Indiana, Pennsylvania, 15701, United States
IU Health Central Indiana Cancer Centers-East

Indianapolis, Indiana, 46219, United States
IU Health Methodist Hospital

Indianapolis, Indiana, 46202, United States
Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States
Intermountain Medical Center

Murray, Utah, 84107, United States
Iowa Methodist Medical Center

Des Moines, Iowa, 50309, United States
John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Lawrence Memorial Hospital

Lawrence, Kansas, 66044, United States
Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017, United States
Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, 31405, United States
Longmont United Hospital

Longmont, Colorado, 80501, United States
MU Health - University Hospital/Ellis Fischel Cancer Center

Columbia, Missouri, 65212, United States
Marshfield Medical Center

Marshfield, Wisconsin, 54449, United States
Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548, United States
Mayo Clinic Health System-Franciscan Healthcare

La Crosse, Wisconsin, 54601, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
McFarland Clinic - Ames

Ames, Iowa, 50010, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Memorial Health University Medical Center

Savannah, Georgia, 31404, United States
Memorial Hospital of South Bend

South Bend, Indiana, 46601, United States
Memorial Medical Center

Modesto, California, 95355, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Sleepy Hollow

Sleepy Hollow, New York, 10591, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Mercy Cancer Center-Elyria

Elyria, Ohio, 44035, United States
Mercy Hospital Saint Louis

St Louis, Missouri, 63141, United States
Mercy Hospital Springfield

Springfield, Missouri, 65804, United States
Mercy San Juan Medical Center

Carmichael, California, 95608, United States
MetroHealth Medical Center

Cleveland, Ohio, 44109, United States
Michiana Hematology Oncology PC-Mishawaka

Mishawaka, Indiana, 46545, United States
Miller-Dwan Hospital

Duluth, Minnesota, 55805, United States
Mills Health Center

San Mateo, California, 94401, United States
Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337, United States
Missouri Baptist Medical Center

St Louis, Missouri, 63131, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Moffitt Cancer Center at SouthShore

Ruskin, Florida, 33570, United States
Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607, United States
Monmouth Medical Center

Long Branch, New Jersey, 07740, United States
Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467, United States
Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461, United States
Mount Sinai Union Square

New York, New York, 10003, United States
MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
NYU Langone Hospital - Brooklyn

Brooklyn, New York, 11220, United States
NYU Langone Hospital - Long Island

Mineola, New York, 11501, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
New Mexico Oncology Hematology Consultants

Albuquerque, New Mexico, 87109, United States
New York-Presbyterian/Brooklyn Methodist Hospital

Brooklyn, New York, 11215, United States
North Coast Cancer Care

Sandusky, Ohio, 44870, United States
North Kansas City Hospital

Kansas City, Missouri, 64116, United States
North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422, United States
NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201, United States
NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026, United States
NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035, United States
Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042, United States
Northwestern University

Chicago, Illinois, 60611, United States
OSF Saint Francis Medical Center

Peoria, Illinois, 61637, United States
OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Peoria, Illinois, 61615, United States
Ochsner Medical Center Jefferson

New Orleans, Louisiana, 70121, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903, United States
Orlando Health Cancer Institute

Orlando, Florida, 32806, United States
Our Lady of The Lake

Baton Rouge, Louisiana, 70808, United States
Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808, United States
Parkview Hospital Randallia

Fort Wayne, Indiana, 46805, United States
Parkview Regional Medical Center

Fort Wayne, Indiana, 46845, United States
PeaceHealth Saint John Medical Center

Longview, Washington, 98632, United States
Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850, United States
Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907, United States
Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401, United States
Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301, United States
Prisma Health Cancer Institute - Eastside

Greenville, South Carolina, 29615, United States
Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605, United States
Prisma Health Cancer Institute - Greer

Greer, South Carolina, 29650, United States
Prisma Health Cancer Institute - Seneca

Seneca, South Carolina, 29672, United States
Prisma Health Cancer Institute - Spartanburg

Boiling Springs, South Carolina, 29316, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505, United States
Providence Saint Vincent Medical Center

Portland, Oregon, 97225, United States
Queen's Medical Center

Honolulu, Hawaii, 96813, United States
Radiation Oncology Associates PC

Fort Wayne, Indiana, 46804, United States
Rapid City Regional Hospital

Rapid City, South Dakota, 57701, United States
Reading Hospital

West Reading, Pennsylvania, 19611, United States
Robert Wood Johnson University Hospital Somerset

Somerville, New Jersey, 08876, United States
Rock Hill Radiation Therapy Center

Rock Hill, South Carolina, 29730, United States
Rocky Mountain Cancer Centers-Boulder

Boulder, Colorado, 80304, United States
Rocky Mountain Cancer Centers-Littleton

Littleton, Colorado, 80120, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rush MD Anderson Cancer Center

Chicago, Illinois, 60612, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Rutgers New Jersey Medical School

Newark, New Jersey, 07101, United States
Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687, United States
Saint Francis Hospital

Federal Way, Washington, 98003, United States
Saint Francis Medical Center

Cape Girardeau, Missouri, 63703, United States
Saint George Regional Medical Center

St. George, Utah, 84770, United States
Saint Helena Hospital

St. Helena, California, 94574, United States
Saint Joseph's/Candler - Bluffton Campus

Bluffton, South Carolina, 29910, United States
Saint Luke's Cancer Center - Allentown

Allentown, Pennsylvania, 18104, United States
Saint Luke's Hospital - Monroe Campus

Stroudsburg, Pennsylvania, 18360, United States
Saint Luke's Hospital - Upper Bucks Campus

Quakertown, Pennsylvania, 18951, United States
Saint Luke's Hospital-Anderson Campus

Easton, Pennsylvania, 18045, United States
Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301, United States
Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303, United States
Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495, United States
Salina Regional Health Center

Salina, Kansas, 67401, United States
Sands Cancer Center

Canandaigua, New York, 14424, United States
Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501, United States
Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601, United States
Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States
Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134, United States
Saskatoon Cancer Centre

Saskatoon, Saskatchewan, S7N 4H4, Canada
Sentara Cancer Institute at Sentara CarePlex Hospital

Hampton, Virginia, 23666, United States
Sentara Norfolk General Hospital

Norfolk, Virginia, 23507, United States
Sentara Virginia Beach General Hospital

Virginia Beach, Virginia, 23454, United States
Shaw Cancer Center

Edwards, Colorado, 81632, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
Skagit Regional Health Cancer Care Center

Mount Vernon, Washington, 98274, United States
Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, 06385, United States
South Shore University Hospital

Bay Shore, New York, 11706, United States
Southern Ohio Medical Center

Portsmouth, Ohio, 45662, United States
Sparta Cancer Treatment Center

Sparta, New Jersey, 07871, United States
Spartanburg Medical Center

Spartanburg, South Carolina, 29303, United States
Spokane Valley Cancer Center-Mayfair

Spokane, Washington, 99208, United States
Spokane Valley Cancer Center-Mission

Spokane, Washington, 99216, United States
Springfield Memorial Hospital

Springfield, Illinois, 62781, United States
Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States
State University of New York Upstate Medical University

Syracuse, New York, 13210, United States
Summa Health Medina Medical Center

Medina, Ohio, 44256, United States
Summa Health System - Akron Campus

Akron, Ohio, 44304, United States
Summa Health System - Barberton Campus

Barberton, Ohio, 44203, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn

Auburn, California, 95603, United States
Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Cameron Park, California, 95682, United States
Sutter Cancer Centers Radiation Oncology Services-Roseville

Roseville, California, 95661, United States
Sutter Medical Center Sacramento

Sacramento, California, 95816, United States
Temple University Hospital

Philadelphia, Pennsylvania, 19140, United States
The Cancer Center of Hawaii-Liliha

Honolulu, Hawaii, 96817, United States
The Cancer Institute of New Jersey Hamilton

Hamilton, New Jersey, 08690, United States
The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202, United States
The Kirklin Clinic at Acton Road

Birmingham, Alabama, 35243, United States
The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061, United States
The University of Kansas Cancer Center-South

Kansas City, Missouri, 64131, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
Touro Infirmary

New Orleans, Louisiana, 70115, United States
Tri-Cities Cancer Center

Kennewick, Washington, 99336, United States
Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106, United States
Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States
Tulane University School of Medicine

New Orleans, Louisiana, 70112, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
UC San Diego Health System - Encinitas

Encinitas, California, 92024, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UCSF Medical Center-Mission Bay

San Francisco, California, 94158, United States
UCSF Medical Center-Mount Zion

San Francisco, California, 94115, United States
UH Seidman Cancer Center at Firelands Regional Medical Center

Sandusky, Ohio, 44870, United States
UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060, United States
UH Seidman Cancer Center at Southwest General Hospital

Middleburg Heights, Ohio, 44130, United States
UH Seidman Cancer Center at UH Avon Health Center

Avon, Ohio, 44011, United States
UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122, United States
UHHS-Westlake Medical Center

Westlake, Ohio, 44145, United States
UM Baltimore Washington Medical Center/Tate Cancer Center

Glen Burnie, Maryland, 21061, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442, United States
UM Upper Chesapeake Medical Center

Bel Air, Maryland, 21014, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
UPMC Altoona

Altoona, Pennsylvania, 16601, United States
UPMC Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146, United States
UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121, United States
UPMC Cancer Center at UPMC McKeesport

McKeesport, Pennsylvania, 15132, United States
UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, 16346, United States
UPMC Cancer Center-Natrona Heights

Natrona Heights, Pennsylvania, 15065, United States
UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601, United States
UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505, United States
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050, United States
UPMC Hillman Cancer Center in Coraopolis

Moon Township, Pennsylvania, 15108, United States
UPMC Jameson

New Castle, Pennsylvania, 16105, United States
UPMC Jefferson Regional Radiation Oncology

Pittsburgh, Pennsylvania, 15236, United States
UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109, United States
UPMC Uniontown Hospital Radiation Oncology

Uniontown, Pennsylvania, 15401, United States
UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, 15301, United States
UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, 15009, United States
UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown, Pennsylvania, 15901, United States
UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States
UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237, United States
UPMC-Saint Clair Hospital Cancer Center

Pittsburgh, Pennsylvania, 15243, United States
UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215, United States
UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232, United States
UT MD Anderson - League City

League City, Texas, 77573, United States
UT MD Anderson - Sugar Land

Sugar Land, Texas, 77478, United States
UT MD Anderson - The Woodlands

Conroe, Texas, 77384, United States
UT MD Anderson - West Houston

Houston, Texas, 77079, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
UTMB Cancer Center at Victory Lakes

League City, Texas, 77573, United States
UW Health Carbone Cancer Center Rockford

Rockford, Illinois, 61114, United States
University Hospitals Parma Medical Center

Parma, Ohio, 44129, United States
University Hospitals Portage Medical Center

Ravenna, Ohio, 44266, United States
University Medical Center New Orleans

New Orleans, Louisiana, 70112, United States
University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States
University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219, United States
University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069, United States
University of Connecticut

Farmington, Connecticut, 06030, United States
University of Illinois

Chicago, Illinois, 60612, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States
University of Michigan - Brighton Center for Specialty Care

Brighton, Michigan, 48116, United States
University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912, United States
University of Michigan Health - West

Wyoming, Michigan, 49519, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Rochester

Rochester, New York, 14642, United States
University of Texas Medical Branch

Galveston, Texas, 77555-0565, United States
University of Washington Medical Center - Montlake

Seattle, Washington, 98195, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718, United States
University of Wisconsin Carbone Cancer Center - Johnson Creek

Johnson Creek, Wisconsin, 53038, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
UofL Health Medical Center Northeast

Louisville, Kentucky, 40245, United States
Utah Cancer Specialists-Salt Lake City

Salt Lake City, Utah, 84106, United States
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Virtua Memorial

Mount Holly, New Jersey, 08060, United States
Virtua Voorhees

Voorhees Township, New Jersey, 08043, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wenatchee Valley Hospital and Clinics

Wenatchee, Washington, 98801, United States
West Michigan Cancer Center

Kalamazoo, Michigan, 49007, United States
West Virginia University Healthcare

Morgantown, West Virginia, 26506, United States
Wexford Health and Wellness Pavilion

Wexford, Pennsylvania, 15090, United States
Wheeling Hospital/Schiffler Cancer Center

Wheeling, West Virginia, 26003, United States
Wilmot Cancer Institute Radiation Oncology at Greece

Rochester, New York, 14606, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.